Deuterated camptothecin compound, and preparation therefor and use thereof

By developing deuterated camptothecin compounds, the problem of high toxicity of camptothecin drugs in the body is solved, and a lower toxic anti-tumor drug load is achieved, which is cleared in the body through its better stability and short half-life, significantly improving the security.

WO2024230646A1PCT designated stage expired Publication Date: 2024-11-14SHANGHAI QILU PHARMACEUTICAL RESEARCH & DEVELOPMENT CENTRE LTD

Patent Information

Application Number
PCT/CN2024/091220
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-04-29
Filing Date
2024-05-06
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing camptothecin drugs have toxicity problems in the body, and the load as anti-tumor drugs is difficult to remove after falling off in the body, resulting in high toxicity.

Method used

A class of deuterated camptothecin compounds and their pharmaceutically acceptable salts have been developed, with better stability and shorter in vivo half-life, which is easier to eliminate in vivo when loaded as antitumor drugs, reducing toxicity.

Benefits of technology

The compound has better stability in plasma and lower in vivo exposure, and has lower toxicity when loaded as an antitumor drug, significantly improving safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024091220_14112024_PF_FP_ABST
    Figure CN2024091220_14112024_PF_FP_ABST
Patent Text Reader

Abstract

Disclosed are a deuterated camptothecin compound as represented by formula II and a pharmaceutically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the deuterated camptothecin compound or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of tumor-related diseases. Such deuterated camptothecin compound has excellent drug activity and pharmacokinetic properties, and has reduced in-vivo toxicity and improved in-vivo safety.
Need to check novelty before this filing date? Find Prior Art

Description

A deuterated camptothecin compound and its preparation and application

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefits and priority of patent application No. 202310506357.6 filed with the State Intellectual Property Office of China on May 6, 2023, patent application No. 202311533730.3 filed with the State Intellectual Property Office of China on November 16, 2023, and patent application No. 202410535444.9 filed with the State Intellectual Property Office of China on April 29, 2024, the entire contents of which are hereby incorporated by reference into this document in their entirety. Technical Field

[0003] The present disclosure belongs to the field of pharmaceutical chemistry, and specifically relates to a class of deuterated camptothecin compounds and pharmaceutically acceptable salts thereof, methods for preparing the same, pharmaceutical compositions containing the deuterated camptothecin compounds or pharmaceutically acceptable salts thereof, and uses of the deuterated camptothecin compounds or pharmaceutically acceptable salts thereof or the pharmaceutical compositions in treating tumor-related diseases. Background Art

[0004] Camptothecin (CPT), a pyrroloquinoline cytotoxic alkaloid, is one of the most studied natural antitumor drugs besides paclitaxel. It is primarily found in the fruit or root bark of the Davidia involucrata plant, a species endemic to my country. In 1985, Hsiang et al. discovered that camptothecin and its derivatives exert their anticancer effects by inhibiting DNA synthesis through topoisomerase I (Topoisomerase I). This led to renewed interest in camptothecin, which subsequently garnered numerous derivatives and became a new hotspot in anticancer research. Since then, a new generation of camptothecins, including 10-hydroxycamptothecin (HCPT), irinotecan, topotecan, SN-38, and belotecan, have been approved for the treatment of various tumors, including colorectal cancer, small cell lung cancer, and ovarian cancer. Research into their indications and dosage forms has also yielded promising results.

[0005] With the development of drug delivery systems, a series of camptothecins that were previously unavailable and had significant side effects have been revived. However, the problem of in vivo toxicity of camptothecins has not been completely eliminated. How to further reduce the toxicity of these drugs remains a major concern.

[0006] Summary of the Invention

[0007] In one aspect, the present disclosure provides a compound of Formula II or a pharmaceutically acceptable salt or a stereoisomer thereof:

[0008] Wherein, R1 is selected from H, halogen, OH, SH, NH2, C 1-4 Alkyl, C 1-4 Haloalkyl or C 1-4 alkoxy;

[0009] R2 is selected from H, halogen, C 1-4 Alkyl or C 1-4 alkoxy;

[0010] Or R1 and R2 are cyclized to -O-(CH2) m -O-, wherein m is selected from 1, 2, 3;

[0011] R3 and R4 are each independently selected from H, C 1-4 Alkyl, C 1-4 Alkoxy, C1-4 haloalkyl or C 1-4 haloalkoxy;

[0012] Or R3 and R4 cyclize to -(CH2) k -, wherein k is selected from 1, 2, 3, 4;

[0013] X is selected from H, OH, HO-CH(R5)-(CH2) p -CO-NH- or -N(R6)(R7), wherein p is selected from 0, 1, 2;

[0014] R5 is selected from H, C 1-4 Alkyl, C 1-4 Haloalkyl, 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl;

[0015] R6 is selected from H, C 1-4 Alkyl or C 1-4 alkyl halide;

[0016] R7 is selected from H or R8-S(O)2-;

[0017] R8 is selected from C 1-4 Alkyl; and

[0018] t is selected from 0, 1, 2, 3, 4, 5.

[0019] In the present disclosure, the expression "R1 and R2 are cyclized to form -O-(CH2) m -O-" means R1 and R2 are connected to form -O-(CH2) m -O-. Expression "R3 and R4 are cyclized to -(CH2) k -" means that R3 and R4 are connected to form -(CH2) k -.

[0020] In any embodiment of the compounds of formula II disclosed herein, R1 is C1-4 alkyl, and R2 is halogen.

[0021] In any of the disclosed embodiments of the compound of formula II, R1 is methyl and R2 is F.

[0022] In any of the disclosed embodiments of the compound of formula II, R1 is H, and R2 is H.

[0023] In any of the disclosed embodiments of the compound of formula II, R1 and R2 are cyclized to -O-CH2-O-.

[0024] In any embodiment of the compounds of formula II disclosed herein, R1 is NH2, and R2 is H or halogen. In any embodiment of the compounds of formula II disclosed herein, R1 is NH2, and R2 is H or F.

[0025] In any of the disclosed embodiments of the compound of formula II, R3 is H, and R4 is H.

[0026] In any embodiment of the compound of formula II disclosed herein, R3 is H, and R4 is C 1-4 alkyl.

[0027] In any of the disclosed embodiments of the compound of formula II, R3 is H, and R4 is methyl.

[0028] In any of the disclosed embodiments of the compound of formula II, R3 and R4 are cyclized to -CH2-CH2-.

[0029] In any embodiment of the compounds of formula II disclosed herein, X is HO-CH(R5)-(CH2) p -CO-NH-, wherein p is selected from 0, 1, and 2.

[0030] In any of the disclosed embodiments of the compound of formula II, X is selected from OH or NH2.

[0031] In any of the disclosed embodiments of the compound of formula II, X is H, and t is 0.

[0032] In any of the disclosed embodiments of the compound of formula II, X is -N(R6)(R7).

[0033] In one embodiment of the compound of formula II disclosed herein, the compound of formula II is a compound of formula IIa or a pharmaceutically acceptable salt or stereoisomer thereof;

[0034] wherein R1, R2, R3, and R4 are as defined in any embodiment of the compound of formula II; and X1 is selected from H, HO-CH(R5)-(CH2)p -CO-, p is selected from 0, 1, 2; R5 is selected from H, C 1-4 alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl.

[0035] In any embodiment of the compound of formula IIa disclosed herein, R1 is selected from methyl or methoxy; or R1 is methyl.

[0036] In any of the embodiments of the compounds of Formula IIa disclosed herein, R2 is selected from F or Cl; or R2 is F.

[0037] In any of the disclosed embodiments of the compound of formula IIa, R1 is methyl and R2 is F.

[0038] In any embodiment of the compounds of formula IIa disclosed herein, R3 and R4 are cyclized to -(CH2) k -, where k is 2.

[0039] In any of the embodiments of the compounds of Formula IIa disclosed herein, R3 is H; and R4 is H.

[0040] In any embodiment of the compounds of formula IIa disclosed herein, X1 is HO-CH(R5)-(CH2) p -CO-, wherein p is selected from 0 or 1, R5 is selected from H, C 1-4 Alkyl or 3-6 membered cycloalkyl.

[0041] In any embodiment of the compounds of formula IIa disclosed herein, X1 is HO-CH(R5)-(CH2) p -CO-, wherein p is selected from 0 or 1, and R5 is selected from H, methyl or cyclopropyl.

[0042] In any of the disclosed embodiments of the compound of formula IIa, X1 is HO-CH(R5)-CO-, and R5 is selected from H or a 3-6 membered cycloalkyl group.

[0043] In any of the disclosed embodiments of the compound of formula IIa, X1 is HO-CH(R5)-CO-, and R5 is selected from H or cyclopropyl.

[0044] In any embodiment of the compound of formula IIa disclosed herein, X1 is HO-CH(R5)-CH2-CO-, and R5 is C 1-4 alkyl.

[0045] In any of the disclosed embodiments of the compound of formula IIa, X1 is HO-CH(R5)-CH2-CO-, and R5 is methyl.

[0046] In any embodiment of the compounds of formula IIa disclosed herein, X1 is selected from the group consisting of: H,

[0047] In some embodiments of the compounds of formula IIa of the present disclosure, the compounds of formula IIa are selected from the following compounds of formula IIa-1 or formula IIa-2, or pharmaceutically acceptable salts thereof, or stereoisomers thereof;

[0048] wherein R1, R2, and X1 are as defined in any embodiment of the compound of formula IIa.

[0049] In some embodiments of the compound of formula IIa of the present disclosure, the compound of formula IIa is selected from the following compounds or pharmaceutically acceptable salts or stereoisomers thereof:

[0050] In one embodiment of the compound of formula II disclosed herein, the compound of formula II is a compound of formula IIb or a pharmaceutically acceptable salt or stereoisomer thereof;

[0051] Wherein, R1 is selected from H, OH, halogen, NH2, C 1-4 Alkyl, C 1-4 Haloalkyl or C 1-4 alkoxy;

[0052] R2 is selected from H, halogen, C 1-4 Alkyl or C 1-4 alkoxy;

[0053] Or R1 and R2 are cyclized to -O-(CH2) m -O-, wherein m is selected from 1, 2, 3;

[0054] R3 and R4 are each independently selected from H, C 1-4 Alkyl or C 1-4 alkoxy;

[0055] Or R3 and R4 cyclize to -(CH2) k -, wherein k is selected from 1, 2, 3;

[0056] X2 is selected from H, OH or -N(R6)(R7);

[0057] R6 is selected from H or C 1-4 alkyl;

[0058] R7 is selected from H or R8-S(O)2-;

[0059] R8 is selected from C 1-4 Alkyl; and

[0060] q is selected from 0, 1, 2, 3, 4.

[0061] In any of the embodiments of the compounds of formula IIb disclosed herein, R1 is selected from methyl, and R2 is selected from H, Cl, F.

[0062] In any embodiment of the compounds of formula IIb disclosed herein, R1 and R2 are cyclized to -O-(CH2) m -O-, wherein m is selected from 1 or 2.

[0063] In any of the disclosed embodiments of the compound of formula IIb, R3 and R4 are both H.

[0064] In any of the disclosed embodiments of the compound of Formula IIb, R3 is H, and R4 is methyl.

[0065] In any of the disclosed embodiments of the compound of formula IIb, X2 is selected from H, OH, NH2, or N(i-Pr)-S(O)2-CH3.

[0066] In any embodiment of the compounds of formula IIb disclosed herein, X2 is selected from H and q is 0; alternatively, X2 is selected from OH or -N(R6)(R7) and q is 0, 1, 2, 3 or 4.

[0067] In any embodiment of the compounds of formula IIb disclosed herein, X2 is selected from OH or -N(R6)(R7); q is 1, 2, 3 or 4; R3 and R4 are both H; R1 is selected from methyl and R2 is selected from H, Cl or F, or R1 and R2 are cyclized to -O-(CH2) m -O-, wherein m is selected from 1 or 2.

[0068] In some embodiments of the compound of formula IIb of the present disclosure, the compound of formula IIb is selected from the following compounds of formula IIb-1 or formula IIb-2;

[0069] In the compounds of Formula IIb-1 and Formula IIb-2, R1, R2, X2 and q are as defined in any of the embodiments of the compounds of Formula IIb.

[0070] In some embodiments of the compound of Formula IIb, Formula IIb is selected from the following compounds or pharmaceutically acceptable salts or stereoisomers thereof;

[0071] In one embodiment of the present disclosure, the compounds of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 and Formula IIb-2 do not include the following compounds;

[0072] On the other hand, the present disclosure provides a pharmaceutical composition comprising a compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0073] In another aspect, the present disclosure provides the use of the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2 or its pharmaceutically acceptable salt or the pharmaceutical composition in the preparation of a drug for treating tumors.

[0074] In another aspect, the present disclosure provides a method for treating tumors, comprising administering an effective amount of the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition to a patient in need thereof.

[0075] In another aspect, the present disclosure provides the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2 or its pharmaceutically acceptable salt or the pharmaceutical composition for treating tumors.

[0076] In another aspect, the present disclosure provides the use of the compound of Formula II, Formula IIa, Formula IIb, Formula IIa-1, Formula IIb-1, Formula IIa-2 or Formula IIb-2 or a pharmaceutically acceptable salt thereof or the pharmaceutical composition in treating tumors.

[0077] It is well known to those skilled in the art that antibody-drug conjugates (ADCs) generally produce toxic effects due to the shedding of a small amount of the payload in the body. However, the compounds disclosed herein, particularly Compound 2, have better stability in plasma, a shorter half-life in vivo, and lower in vivo exposure. As the payload of the ADC, it is more easily eliminated after shedding in the body, resulting in lower toxicity. In addition, toxicity tests disclosed herein have demonstrated that the compounds disclosed herein have lower in vivo toxicity at the same dose, and they exhibit better safety whether used independently as cancer therapeutics or as drugs for preparing ADCs.

[0078] Terminology and Description

[0079] Unless otherwise indicated, the terms used herein have their ordinary meanings in the art. A particular term or phrase should not be construed as ambiguous or unclear unless specifically defined, but rather should be understood in accordance with its ordinary meaning. When a trade name appears in this document, it is intended to refer to the corresponding commercial product or its active ingredient.

[0080] In any embodiment of the compounds of formula II disclosed herein, when R1 and R2 are cyclized to -O-(CH2) m -O-, the compound of formula II is the compound of formula II-1. In formula II of the present disclosure or any embodiment thereof, when R3 and R4 are cyclized to -(CH2) k -, it is in the form of the following formula II-2.

[0081] The term "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and the description includes both occurrence and non-occurrence of the event or circumstance. For example, the term "optionally" substituted means that the group may be unsubstituted or substituted with the specified substituent; whether or not substituted is within the scope of "optionally".

[0082] The term "independently selected" or "each independently selected" means that each substituent in the aforementioned substituent may select a different optional variable from a specified range of options, and is not affected by the selection of other substituents. When a substituent that can be "independently selected" exists in a general chemical formula and has multiple identical substituents, they may still select the same or different optional variables.

[0083] The term "halogen" or "halogen atom" refers to fluorine, chlorine, bromine, or iodine.

[0084] The term "halo" refers to a group in which one or more hydrogen atoms in a substituent are replaced by halogen atoms.

[0085] The term "alkyl" refers to a straight or branched hydrocarbon group in which carbon atoms are connected by single bonds. 1-4 or C 1-6 Alkyl. C 1-4 "Alkyl" means a straight or branched chain alkyl group having 1, 2, 3 or 4 carbon atoms. 1-4 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, and tert-butyl. 1-6 "Alkyl" means a straight or branched chain alkyl group having 1, 2, 3, 4, 5 or 6 carbon atoms. 1-6 Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, and n-hexyl.

[0086] The term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen atom. 1-4 Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl.

[0087] The term "alkoxy" refers to an alkyl-O- group, wherein alkyl is as defined above and includes C 1-4 Alkoxy or C 1-6 Alkoxy. C 1-4 Alkoxy can be understood as "C 1-4 Alkyl-O-", examples of which include but are not limited to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy. 1-6 Alkoxy can be understood as "C 1-6 Alkyl-O-", examples of which include the aforementioned C 1-4 Specific examples of alkoxy include, but are not limited to, n-pentyloxy, neopentyloxy, n-hexyloxy, and the like.

[0088] The term "haloalkoxy" refers to an alkoxy group in which one or more hydrogen atoms are replaced by a halogen atom. 1-4 Examples of haloalkoxy include, but are not limited to, trifluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy.

[0089] The term "cycloalkyl" refers to a cyclic, saturated, monocyclic or polycyclic hydrocarbon group whose carbon atoms are connected by single bonds. The H atoms of the ring carbon atoms are optionally oxo-substituted, i.e., the "-CH2-" radical in the ring is optionally oxo-substituted to form "-C(O)-". A 3- to 6-membered cycloalkyl group refers to a 3-, 4-, 5-, or 6-membered cycloalkyl group, and specific examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0090] The term "heterocycloalkyl" refers to a cycloalkyl group in which one or more (e.g., 2, 3, or 4) ring carbon atoms are substituted by heteroatoms or heteroatom groups (i.e., heteroatom groups containing heteroatoms). The ring carbon atoms refer to carbon atoms that constitute the cyclic skeleton structure; the heteroatoms refer to atoms other than C and H in an organic compound, such as nitrogen atoms (N), oxygen atoms (O), sulfur atoms (S), phosphorus atoms (P), or boron atoms (B). The heteroatoms such as nitrogen atoms and sulfur atoms may be oxidized, and the nitrogen atoms may be quaternized; examples of the heteroatom groups include, but are not limited to, -S(=O)2-, -S(=O)-, and optionally substituted -NH-, -S(=O)(=NH)-, -C(=O)NH-, -C(=NH)-, -S(=O)2NH-, S(=O)NH-, or -NHC(=O)NH-. 3-6 membered heterocycloalkyl refers to a 3-, 4-, 5- or 6-membered heterocycloalkyl group, specific examples of which include but are not limited to aziridine, oxirane, thiirane, azetidinyl, oxetanyl, thietanyl, azolanyl, oxolanyl, thiolanyl, piperazinyl, piperidinyl, oxhexyl, morpholinyl, and 1,4-dioxanyl.

[0091] The term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product resulting, directly or indirectly, from combination of the specified ingredients in the specified amounts. Those skilled in the art can modify the actual dosage levels of the active ingredients in the pharmaceutical compositions of the present disclosure so as to achieve the desired therapeutic response in the amount of the active compound obtained, tailored to the specific patient, composition, and route of administration.

[0092] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0093] The term "pharmaceutically acceptable salt" refers to a salt of a pharmaceutically acceptable acid or base, including a salt formed between a compound and an inorganic acid or organic acid, and a salt formed between a compound and an inorganic base or an organic base.

[0094] The term "excipient" generally refers to a carrier, diluent, and / or vehicle required to formulate an effective pharmaceutical composition.

[0095] The term "effective amount" refers to an amount of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof, to treat a disease or condition at a reasonable benefit / risk ratio applicable to any medical treatment. The amount of a compound of the present disclosure that constitutes an "effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art based on their own knowledge and this disclosure.

[0096] In the present disclosure, the substituent Indicates the position of attachment of the substituent to the parent structure or other fragment. A dash "-" in a substituent structure is used to indicate the point of attachment of the substituent, for example, -CH3 indicates that the group is attached to the parent structure or other fragment through a C atom. Indicates the absolute configuration of a stereocenter, i.e., R or S configuration.

[0097] In this disclosure, chemical bonds depicted by solid and dashed lines Whether it represents a single bond or a double bond can be determined based on the valence of the atoms at both ends of the chemical bond within a range known to those skilled in the art.

[0098] In the present disclosure, the "isomers" include geometric isomers and stereoisomers, such as atropisomers, cis-trans isomers, enantiomers, diastereomers, tautomers, and racemic mixtures and other mixtures thereof, all of which fall within the scope of the present disclosure. The term "enantiomer" refers to stereoisomers that are mirror images of each other. The term "tautomer" refers to a type of functional group isomer that has different hydrogen attachment points due to one or more double bond displacements, for example, a ketone and its enol form are keto-enol tautomers. The term "diastereomer" refers to a stereoisomer in which the molecule has two or more chiral centers and is not a mirror image of the other molecules. The term "cis-trans isomer" refers to different spatial configurations in which double bonds or single bonds of ring carbon atoms in a molecule cannot rotate freely. The term "atropisomer" refers to stereoisomers that can be separated because single bond rotation is hindered or rotates very slowly.

[0099] Stereoisomers of the disclosed compounds can be prepared through chiral synthesis, chiral reagents, or other conventional techniques. For example, one enantiomer of a compound disclosed herein can be prepared through asymmetric catalysis or chiral auxiliary derivatization techniques. Alternatively, a single stereoisomer of the compound can be obtained from a mixture using chiral resolution techniques. Alternatively, the enantiomers can be prepared directly using chiral starting materials. Separation of the optically pure compounds disclosed herein is typically accomplished using preparative chromatography, employing chiral chromatographic columns to achieve the purpose of separating chiral compounds.

[0100] In this disclosure, the solution concentration unit "M" represents mol / L, "mM" represents mmol / L, and "nM" represents nmol / L. The solution concentration unit "N" represents normality, which is expressed as the number of gram equivalents of solute contained in 1 liter of solution and is represented by the symbol N. For example, if 1 liter of concentrated hydrochloric acid contains 12.0 gram equivalents of hydrochloric acid (HCl), the concentration is 12.0N. Normality = gram equivalents of solute / solution volume (liters).

[0101] The chemical abbreviations used in this disclosure and the chemical names they refer to are as follows: Example

[0102] The present disclosure is further described in detail below through specific preparation examples and biological experiments. However, it should be understood that these examples and biological experiments are only for specific illustration purposes and should not be understood as limiting the present disclosure in any form. It is clear to those skilled in the art that, hereinafter, unless otherwise specified, the materials used are well known in the art and can be purchased from the market or obtained by those skilled in the art according to published literature or conventional methods. Unless otherwise stated, all reactions of the present disclosure are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, and the solvent is a dry solvent, wherein: (i) the temperature is expressed in degrees Celsius (°C), and the operation is carried out at room temperature, which generally refers to 15-35°C, preferably 20-30°C, and more preferably 20-25°C; (ii) the removal of the solvent is carried out by reduced pressure evaporation on a rotary evaporator, and the bath temperature is not higher than 60°C; (iii) the reaction process is tracked by thin layer chromatography (TLC); (iv) the final product has a satisfactory hydrogen nuclear magnetic resonance spectrum ( 1 H-NMR) and / or mass spectrometry (MS) data.

[0103] Example 1 Preparation of Compound 1

[0104] Step 1:

[0105] 86.4 mL of 2,2,6,6-tetramethylpiperidine was added to a 3 L three-necked flask, followed by 1 L of anhydrous tetrahydrofuran. The system was cooled to -78°C and allowed to react for 15 minutes. 272 ​​mL of a 2.5 M solution of n-butyllithium in petroleum ether was added and allowed to react for 30 minutes. 32 g of compound L-1 was dissolved in 200 mL of anhydrous tetrahydrofuran and added to the system, allowing to react for 1 hour. 50 mL of 1-penten-3-one was dissolved in 200 mL of anhydrous tetrahydrofuran and added to the system, allowing to react for 1 hour. After TLC monitoring of the reaction, 640 mL of 4N hydrochloric acid was added and the mixture was extracted with ethyl acetate. The organic phases were combined, washed with saturated sodium bicarbonate aqueous solution, saturated brine, and dried over anhydrous sodium sulfate. The system was concentrated in vacuo and purified by column chromatography to obtain 21 g of compound L-2 in a 49% yield. ESI-MS m / z: 253.68, [M+H] + .

[0106] 1 H NMR(400MHz, CDCl3) δ6.99(s,1H),6.13(dd,J=17.3,10.6Hz,1H),5.29(d,J=7.0Hz,1H),5.26(s,1H ),3.99(s,3H),2.73(s,2H),2.04(dt,J=14.8,7.3Hz,1H),1.98–1.87(m,1H),0.91(t,J=7.3Hz,3H).

[0107] Step 2

[0108] 21g of compound L-2 was added to a 1L three-necked flask, followed by 400mL of anhydrous ethanol. After cooling the system to 0°C, 14.21g of sodium borodeuteride was added, stirred for 15 minutes, and then warmed to room temperature for 12 hours. TLC monitored the reaction completion, and 30mL of 1N hydrochloric acid was added. The mixture was extracted with dichloromethane, and the organic phases were combined and washed sequentially with saturated sodium bicarbonate aqueous solution and saturated brine, and dried over anhydrous sodium sulfate. After vacuum concentration, the system was purified by column chromatography to obtain 17g of compound L-3 as a transparent viscous liquid, with a yield of 80%. ESI-MS m / z: 259.73, [M+H] + . 1 H NMR(400MHz, CDCl3) δ6.99(s,1H),6.13(dd,J=17.3,10.6Hz,1H),5.29(d,J=7.0Hz,1H),5.26(s,1H ),3.99(s,3H),2.73(s,2H),2.04(dt,J=14.8,7.3Hz,1H),1.98–1.87(m,1H),0.91(t,J=7.3Hz,3H).

[0109] Step 3:

[0110] 2 g of compound L-3 was added to a 250 mL round-bottom flask, along with 100 mL of dichloromethane. The system was cooled to -78°C and ozone was introduced. After TLC monitoring of the reaction, 0.5 mL of dimethyl sulfide was added, and the mixture was warmed to room temperature and stirred for 30 minutes. The system was concentrated in vacuo and purified by column chromatography to obtain 1.9 g of compound L-4 in a 95% yield. The product was used directly in the next reaction without further purification. ESI-MS m / z: 261.70, [M+H] + .

[0111] 1 H NMR (400MHz, CDCl3) δ7.15 (s, 1H), 5.19 (d, J = 4.8Hz, 1H), 3.96 (s, 3H), 3.21 (d, J = 4.8Hz, 1H), 2.64 (s, 1H), 1.80 (q, J = 7.5Hz, 2H), 0.92 (t, J = 7.5Hz, 3H).

[0112] Step 4:

[0113] 12g of compound L-4 was added to a 1L single-necked flask, followed by 240mL of dichloromethane. The mixture was stirred for 30 minutes and then cooled to 0°C. 286mg of 2,2,6,6-tetramethylpiperidinyl oxide, 616mg of sodium bicarbonate, 654mg of potassium bromide, and 18mL of water were added and stirred for 15 minutes. 120mL of aqueous sodium hypochlorite solution (>7.5wt%) was added and allowed to react for 30 minutes. TLC monitored the reaction for completion, and 12g of sodium bisulfite was added. The mixture was extracted with dichloromethane. The organic phases were combined, washed with water, saturated brine, and dried over anhydrous sodium sulfate. The system was concentrated in vacuo and purified by column chromatography to yield 6.6g of compound L-5 in a 55% yield. ESI-MS m / z: 259.68, [M+H] + .

[0114] 1 H NMR (400MHz, CDCl3) δ7.20 (s, 1H), 4.00 (s, 3H), 3.64 (s, 1H), 1.79 (q, J = 7.4Hz, 2H), 0.97 (t, J = 7.4Hz, 3H).

[0115] Step 5:

[0116] Under a carbon monoxide atmosphere, 3g of compound L-5 was added to a 100mL three-necked flask. 286mg of 1,3-bis(diphenylphosphino)propane, 2.4g of potassium carbonate, 129mg of palladium acetate, 15mL of N,N-dimethylformamide, and 30mL of deuterated methanol were also added. The system was heated to 65°C and reacted for 12 hours. TLC monitored the reaction completion. 20mL of 1N hydrochloric acid was added, and the mixture was extracted with ethyl acetate. The organic phases were combined, washed sequentially with saturated sodium bicarbonate aqueous solution and saturated brine, and dried over anhydrous sodium sulfate. The system was concentrated in vacuo and purified by column chromatography to obtain 1.33g of compound L-6 in a 40% yield. ESI-MS m / z: 286.29, [M+H] + .

[0117] 1 H NMR (400MHz, CDCl3) δ7.98 (d, J = 2.0 Hz, 1H), 4.09 (d, J = 2.0 Hz, 3H), 3.71 (d, J = 2.6 Hz, 1H), 1.88–1.75 (m, 2H), 0.96 (td, J = 7.3, 1.9 Hz, 3H).

[0118] Step 6:

[0119] 1 g of compound L-6 was added to a 50 mL two-necked flask, along with 1.05 g of sodium iodide and 10 mL of acetonitrile. The system was cooled to 0°C and stirred for 30 minutes. 0.89 mL of trimethylsilyl chloride was added, and the system was warmed to room temperature for 12 hours. TLC monitored the reaction for completion. 40 mL of water and 1 mL of saturated sodium bisulfite aqueous solution were added, and the mixture was stirred for 1 hour. The mixture was extracted with dichloromethane and dried over anhydrous sodium sulfate. The system was concentrated in vacuo and purified by column chromatography to yield 800 mg of compound L-7 in an 84% yield. ESI-MS m / z: 272.27, [M+H] + .

[0120] 1 H NMR (400MHz, CDCl3) δ10.03 (s, 1H), 7.32 (s, 1H), 3.90 (s, 1H), 1.81 (dd, J = 14.5, 7.2Hz, 2H), 0.99 (t, J = 7.4Hz, 3H).

[0121] Step 7:

[0122] 620 mg of compound L-7 was added to a 25 mL two-necked flask, along with 1.48 g of cesium carbonate, 8 mL of dimethyl sulfoxide, and 1.67 mL of tert-butyl acrylate. The system was heated to 50°C and reacted for 12 hours. TLC monitored the reaction for completion. 1 mL of concentrated hydrochloric acid was added, followed by 40 mL of water. The mixture was extracted with dichloromethane and dried over anhydrous sodium sulfate. After vacuum concentration, preparative SPC chiral separation (SFC-350 (Waters), column: AS 25*250 mm, 10 μm, mobile phase: CO2 / MEOH = 65 / 35, flow rate: 200 mL / min) afforded 468 mg of compound L-8 in a 55% yield. ESI-MS m / z: 365.38, [M+H] + .

[0123] Step 8:

[0124] 200 mg of compound L-8 was added to a 10 mL single-necked bottle, followed by 5 mL of toluene and 0.5 mL of trifluoroacetic acid. The system was heated to 110°C and reacted for 2 hours. TLC monitored the reaction completion. The system was concentrated in vacuo and purified by column chromatography to obtain 140 mg of compound L-9 in a 98% yield. ESI-MS m / z: 265.26, [M+H] + .

[0125] Step 9:

[0126] 300 mg of compound L-9 was added to a 25 mL single-necked flask, along with 266 mg of N-(5-methyl-6-fluoro-8-amino-1-oxo-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide, 9 mL of toluene, 770 mL of o-cresol, and 133 mg of pyridinium p-toluenesulfonate. The system was heated to 110°C and reacted for 18 hours. TLC monitored the reaction completion. The system was concentrated in vacuo and purified by column chromatography (dichloromethane:methanol = 10:1) to afford 443 mg of compound L-10, in an 81% yield.

[0127] Step 10:

[0128] 443 mg of intermediate compound L-10 was added to a 25 mL single-necked flask, followed by 7 mL of purified water and 2.2 mL of methanesulfonic acid. The atmosphere was replaced with nitrogen. The system was heated to 85°C and reacted for 10 hours. TLC monitored the reaction completion. The system was concentrated under vacuum and purified by column chromatography (dichloromethane:methanol) to afford 141 mg of compound 1 in a 35% yield. ESI-MS m / z: 437.47, [M+H] + .

[0129] 1 H NMR(400MHz,D2O)δ7.20–7.06(m,2H),5.42–5.14(m,5H),3.30(dd,J=18.1,4.0Hz,1H),3.06–2.91 (m,1H),2.69(s,2H),2.62–2.47(m,1H),2.18(s,3H),1.80(q,J=7.3Hz,2H),0.79(t,J=7.4Hz,3H).

[0130] Example 2 Preparation of Compound 2

[0131] To a mixture of anhydrous sodium sulfate (2.25 eq), ethyl 2-oximecyanoacetate (2.25 eq), 2-hydroxyacetic acid (1.45 eq), and the methanesulfonate salt of compound 1 (100 mg) was added 2.4 mL of water and 3.0 mL of tetrahydrofuran. After stirring at room temperature for 15 minutes, N-methylmorpholine (1.10 eq) was added. After stirring at room temperature for 15 minutes, EDCI (2 eq) was added and stirred at room temperature for 3 hours. The reaction of compound 1 was monitored by HPLC for completion. The mixture was filtered, the filter cake was air-dried, and then purified by silica gel column chromatography (DCM:MeOH) to obtain the title compound.

[0132] 1H NMR (400MHz, DMSO) δ8.41(d,J=8.9Hz,1H),7.77(d,J=11.0Hz,1H),7.30(s,1H),6.52(s,1H),5.58(d,J=5.4Hz,1H),5.49(t,J=5.7Hz,1H),5.20(t,J =13.9Hz,2H),3.96(d,J=5.5Hz,2H),3.28–3.05(m,2H),2.39(s,3H),2.29 –2.11(m,2H),1.96–1.78(m,2H),0.87(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :496.1.

[0133] Example 3 Preparation of Compound 3

[0134] Referring to the preparation method of Example 2, using (R)-2-cyclopropyl-2-hydroxyacetic acid as raw material, 52 mg of compound 3 was prepared with a yield of 52%.

[0135] 1 H NMR (400MHz, DMSO-d6) δ8.36(d,J=8.4Hz,1H),7.78(d,J=10.9Hz,1H),7.31(s,1H),6.52(s, 0H),5.58–5.48(m,1H),5.38(d,J=5.3Hz,1H),5.21(q,J=19.0Hz,2H),3.62(d,J=5.2Hz,1H), 3.16(dd,J=11.2,5.7Hz,3H),2.39(s,4H),2.22–2.12(m,3H),1.86(dt,J=14.3,7.1Hz,2H), 1.14(q,J=7.3Hz,2H),0.87(t,J=7.2Hz,3H),0.38(dd,J=20.9,5.6Hz,4H).MS(ESI)m / z[M+H] + :536.2.

[0136] Example 4 Preparation of Compound 4

[0137] Referring to the preparation method of Example 2, (S)-2-cyclopropyl-2-hydroxyacetic acid was used as the starting material to prepare 54 mg of compound 4 in a yield of 54%.

[0138] 1H NMR (400MHz, DMSO-d6) δ8.37(d,J=9.0Hz,1H),7.77(d,J=11.0Hz,1H),7.30(s,1H),6.51 (s,1H),5.58(q,J=6.7Hz,1H),5.49(d,J=5.2Hz,1H),5.35–5.06(m,2H),3.60(t,J=5.7Hz ,1H),3.17(q,J=17.2Hz,2H),2.39(s,3H),2.16(d,J=6.1Hz,2H),1.85(dq,J=14.2,7.1H z,2H),1.24(q,J=8.1Hz,1H),0.87(t,J=7.3Hz,3H),0.59–0.32(m,4H).MS(ESI)m / z[M+H] + :536.2.

[0139] Example 5 Preparation of Compound 5

[0140] Referring to the preparation method of Example 2, (R)-3-hydroxybutyric acid was used as the starting material to prepare 55 mg of compound 5 with a yield of 56%.

[0141] 1 H NMR (400MHz, DMSO-d6) δ8.42(d,J=8.7Hz,1H),7.78(d,J=11.0Hz,1H),7.30(s,1H),6.52(s, 1H),5.55(dt,J=9.3,5.0Hz,1H),5.29–5.12(m,2H),4.66(d,J=4.7Hz,1H),4.05(dt,J=12.1 ,6.0Hz,1H),3.25–3.09(m,2H),2.39(s,3H),2.33–2.17(m,2H),2.13(dd,J=10.7,5.4Hz,2H ),1.86(hept,J=7.1Hz,2H),1.09(d,J=6.2Hz,3H),0.87(t,J=7.3Hz,3H).MS(ESI)m / z[M+H] + :524.2.

[0142] Example 6 Preparation of Compound 6

[0143] Referring to the preparation method of Example 2, (S)-3-hydroxybutyric acid was used as the starting material to prepare 51 mg of compound 6 with a yield of 52%.

[0144] 1H NMR (400MHz, DMSO-d6) δ8.41(d,J=8.7Hz,1H),7.78(d,J=11.0Hz,1H),7.30(s,1H),6.53(s ,1H),5.57(dt,J=8.8,4.5Hz,1H),5.22(d,J=2.7Hz,2H),4.64(d,J=4.5Hz,1H),4.05(dt,J =11.9,6.1Hz,1H),3.16(t,J=5.7Hz,2H),2.39(s,3H),2.32–2.17(m,2H),2.17–2.04(m,2H ),1.86(hept,J=7.1Hz,2H),1.08(d,J=6.1Hz,3H),0.87(t,J=7.3Hz,3H).MS(ESI)m / z[M+H] + :524.2.

[0145] Example 7 Preparation of Compound 7

[0146] Compound 7-1 (87 mg, 1 eq), compound 7-2 (144 mg, 1.1 eq), pyridinium p-toluenesulfonate (50 mg, 0.4 eq), acetic acid (2.6 mL, 30 V), and toluene (2.6 mL, 30 V) were placed in a reaction flask and reacted at 110° C. for 18 hours. The reaction was complete as monitored by TLC. The solvent was removed by rotary evaporation, and the mixture was separated and purified by silica gel column chromatography (dichloromethane:methanol) to obtain 123 mg of compound 7 with a yield of 61%.

[0147] 1 H NMR (400MHz, DMSO-d6) δ7.72(d,J=9.0Hz,1H),7.29(d,J=9.0Hz,1H),7.17(s,1H),6.45(s,1H),5.65(s,2H),5.16(s,2H),3.04 (t,J=6.1Hz,2H),2.75(t,J=6.1Hz,2H),2.08–1.95(m,2H),1.85(hept,J=7.1Hz,2H),0.88(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :406.1.

[0148] Example 8 Preparation of Compound 8

[0149] Referring to the preparation method of Example 7, 127 mg of compound 8 was prepared using compounds 8-1 and 7-2 as starting materials with a yield of 60%.

[0150] 1H NMR (400MHz, DMSO-d6) δ8.41(d,J=8.7Hz,1H),7.78(d,J=11.0Hz,1H),7.30(s,1H),6.53(s ,1H),5.57(dt,J=8.8,4.5Hz,1H),5.22(d,J=2.7Hz,2H),4.64(d,J=4.5Hz,1H),4.05(dt,J =11.9,6.1Hz,1H),3.16(t,J=5.7Hz,2H),2.39(s,3H),2.32–2.17(m,2H),2.17–2.04(m,2H ),1.86(hept,J=7.1Hz,2H),1.08(d,J=6.1Hz,3H),0.87(t,J=7.3Hz,3H).MS(ESI)m / z[M+H] + :424.1.

[0151] Example 9 Preparation of Compound 9

[0152] Step 1:

[0153] 250 mg of compound 9-1, 300 mg of compound 7-2, 7.5 mL of acetic acid, 7.5 mL of toluene, and 68 mg of pyridinium p-toluenesulfonate were added to a 50 mL single-necked flask and reacted at 110°C for 18 hours. The reaction was monitored for completion by TLC. The solvent was evaporated under reduced pressure and the product was purified by silica gel column chromatography (DCM:MeOH) to obtain 386 mg of compound 9-3 in an 81% yield. MS (ESI) m / z [M+H] + :480.2.

[0154] Step 2:

[0155] 380 mg of compound 9-3 was added to a 100 mL single-necked bottle, along with 7.6 mL of purified water and 3.8 mL of methanesulfonic acid. The mixture was reacted at 85°C under nitrogen for 10 hours. TLC confirmed the reaction was complete, and the mixture was cooled to room temperature. 22.8 mL of methanol was added, stirred at room temperature for 2 hours, and filtered to obtain the crude product. This was then separated and purified using silica gel column chromatography (dichloromethane:methanol) to afford 148 mg of compound 9, in a 35% yield.

[0156] 1H NMR(400MHz,D2O)δ7.20–7.06(m,2H),5.42–5.14(m,5H),3.30(dd,J=18.1,4.0Hz,1H),3.06–2.91 (m,1H),2.69(s,2H),2.62–2.47(m,1H),2.18(s,3H),1.80(q,J=7.3Hz,2H),0.79(t,J=7.4Hz,3H). MS(ESI)m / z[M+H]+:438.2.

[0157] Example 10 Preparation of Compound 10

[0158] The preparation method of Example 9 was followed, and compound 10-1 and compound 7-2 were used as raw materials to prepare 70 mg of compound 10 with a yield of 34%.

[0159] 1 H NMR(400MHz,DMSO-d6)δ8.32(d,J=8.4Hz,1H),8.20(dd,J=8.4,1.2Hz,1H),7.93 -7.84(m,1H),7.79(t,J=7.6Hz,1H),7.35(s,1H),6.56(s,1H),5.42(s,2H),3.98 (p,J=6.7Hz,1H),3.50(t,J=8.0Hz,2H),3.42-3.35(m,2H),3.00(s,3H),1.88(he pt,J=7.3Hz,2H),1.15(d,J=6.7Hz,6H),0.88(t,J=7.3Hz,3H).MS(ESI)m / z[M+H] + :514.2.

[0160] Example 11 Preparation of Compound 11

[0161] The preparation method of Example 9 was followed, and compound 11-1 and compound 7-2 were used as raw materials to prepare 80 mg of compound 11 with a yield of 37%.

[0162] 1H NMR (500MHz, DMSO-d6) δ0.88(t,J=7.25Hz,3H),1.32(t,J=7.5Hz,3H),1.85(m,2H),3.11(q,J=7.5Hz,2 H), 5.26 (s, 2H), 6.48 (s, 1H), 7.23 (s, 1H), 7.41 (d, J = 10.0Hz, 2H), 8.01 (d, J = 10.0Hz, 1H), 10.3 (s, 1H). MS(ESI)m / z[M+H] + :395.1.

[0163] Example 12 Preparation of Compound 12

[0164] 255 mg of compound 12-1, 300 mg of compound 7-2, 7.5 mL of acetic acid, 7.5 mL of toluene, and 68 mg of pyridinium p-toluenesulfonate were added to a 50 mL single-necked flask and reacted at 110°C for 18 hours. The reaction was monitored for completion by TLC. The solvent was evaporated under reduced pressure, and the mixture was purified by silica gel column chromatography (DCM:MeOH) to obtain 330 mg of compound 12-3, in a 70% yield.

[0165] 1 H NMR(400MHz,DMSO-d6)δ7.63(s,1H),7.51(s,1H),7.24(s,1H),6.50(s,1H),6.30(s,2H),5.26(s,2H ),3.81(d,J=5.9Hz,2H),3.22(s,2H),1.98(d,J=6.7Hz,4H),0.88(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :471.1.

[0166] 300 mg of intermediate compound 12-3 was dissolved in 15 mL of 10% sulfuric acid and reacted at 110°C for 48 hours. After TLC monitoring, the reaction was adjusted to neutrality by adding saturated aqueous sodium carbonate. The mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was separated and purified by silica gel column chromatography (DCM:MeOH) to obtain 89 mg of compound 12, a yield of 31%.

[0167] 1H NMR(400MHz,DMSO-d6)δ7.63(s,1H),7.50(s,1H),7.24(s,1H),6.48(s,1H),6.28(s,2H),5.32-5.19(m ,2H),3.51-3.46(m,2H),3.17-3.13(m,2H),1.92–1.76(m,4H),0.88(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :453.2.

[0168] Example 13 Preparation of Compound 13

[0169] Referring to the preparation method of Example 12, compound 13-1 and compound 7-2 were used as raw materials to prepare 74 mg of compound 13 with a two-step yield of 16%.

[0170] 1 H NMR(400MHz,DMSO-d6)δ7.63(s,1H),7.50(s,1H),7.24(s,1H),6.48(s,1H),6.28(s,2H),5.32-5.19(m ,2H),3.51-3.46(m,2H),3.17-3.13(m,2H),1.94–1.76(m,6H),0.88(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :467.2.

[0171] Example 14 Preparation of Compound 14

[0172] Step 1:

[0173] 213 mg of compound 14-1, 300 mg of compound 7-2, 7.5 mL of acetic acid, 7.5 mL of toluene, and 68 mg of pyridinium p-toluenesulfonate were added to a 50 mL single-necked flask and reacted at 110°C for 18 hours. The reaction was monitored for completion by TLC. The solvent was removed by evaporation, and the product was purified by silica gel column chromatography (DCM:MeOH) to obtain 300 mg of compound 14-3 in a 68% yield. MS (ESI) m / z [M+H]+: 443.1.

[0174] Step 2:

[0175] 300 mg of compound 14-3 was dissolved in 3 mL of N,N-dimethylformamide, and sodium azide (48 mg, 1.1 eq) was added. The mixture was allowed to react at 80°C for 16 hours. The reaction was monitored by TLC until complete. The mixture was cooled to room temperature, and 18 mL of water was added. The mixture was extracted with ethyl acetate. The organic phases were combined, washed with water, dried over anhydrous sodium sulfate, filtered, and dried to dryness. This afforded 186 mg of crude compound 14-4, a 63% yield. MS (ESI) m / z [M+H]+: 436.1.

[0176] Step 3:

[0177] 186 mg of compound 14-4 was dissolved in 4 mL of tetrahydrofuran, and triphenylphosphine (134 mg, 1.2 eq) was added. The mixture was stirred at room temperature for 4 hours. The reaction was completed after monitoring by TLC. Hydrochloric acid (4 M, 1 mL) was added to the reaction system, and the mixture was reacted at 55° C. for 16 hours. The mixture was concentrated under reduced pressure and purified by reverse phase column (SEPA FLASH SW025, Spherical C18, 20-45 μm, The residue was separated and purified by mobile phase A: 0.05% formic acid / water, mobile phase B: acetonitrile; mobile phase A: mobile phase B = 40:60, flow rate 20 mL / min) to obtain 63 mg of compound 14, yield: 35%.

[0178] 1 H NMR(400MHz,DMSO-d6)δ8.62(s,2H),8.45(s,1H),7.50(s,1H),7.25(s,1H),6.48(s,1H),6.28(s,2H),5.41(s, 2H),5.20(s,2H),4.70(d,J=6.0Hz,2H),1.86(tt,J=14.2,6.1Hz,2H),0.88(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :424.1.

[0179] Example 15 Preparation of Compound 15

[0180] Referring to the preparation method of Example 14, 50 mg of compound 15 was prepared using compounds 15-1 and 7-2 as starting materials with a three-step yield of 11%.

[0181] 1H NMR (400MHz, DMSO-d6) δ8.62(s,2H),8.45(s,1H),7.50(s,1H),7.25(s,1H),6.48(s,1H),6.28(s,2H),5.41(s,2H),5. 20(s,2H),3.51-3.46(m,2H),3.17-3.13(m,2H),1.86(tt,J=14.2,6.1Hz,2H),0.88(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :438.2.

[0182] Example 16 Preparation of Compound 16

[0183] 1 g of compound 16-1, 1.5 g of compound 7-2, 30 mL of acetic acid, 30 mL of toluene, and 340 mg of pyridinium p-toluenesulfonate were added to a 250 mL single-necked flask and reacted at 110°C for 18 hours. The reaction was monitored for completion by TLC. The solvent was removed and the product was purified by silica gel column chromatography (dichloromethane:methanol) to obtain 1.6 g of the target intermediate compound 16-3 in a 75% yield. MS (ESI) m / z [M+H]+: 431.1.

[0184] Compound 16-3 (1.6 g) was dissolved in 16 mL of N,N-dimethylformamide, and sodium azide (256 mg, 1.1 eq) was added. The mixture was allowed to react at 80°C for 16 hours. TLC confirmed the reaction was complete. The mixture was cooled to room temperature, and 96 mL of water was added. The mixture was extracted with ethyl acetate. The combined organic phases were washed with water, dried over anhydrous sodium sulfate, filtered, and dried to dryness. This afforded 1.1 g of crude compound 16-4 in a 68% yield. MS (ESI) m / z [M+H]+: 438.2.

[0185] 1.1 g of compound 16-4 was dissolved in 22 mL of tetrahydrofuran, and triphenylphosphine (0.79 g, 1.2 eq) was added. The mixture was stirred at room temperature for 4 hours. The reaction was completed after monitoring by TLC. Hydrochloric acid (4 M, 5 mL) was added to the reaction system, and the mixture was reacted at 55° C. for 16 hours. The mixture was concentrated under reduced pressure and separated and purified using a reverse phase column (instrument model SEPA FLASH SW025, chromatographic column: Spherical C18, 20-45 μm, Mobile phase A: 0.05% formic acid / water, mobile phase B: acetonitrile; mobile phase A: mobile phase B = 45:55, flow rate 20 mL / min), to obtain 0.58 g of compound 16, yield: 56%.

[0186] 1H NMR(400MHz, DMSO-d6)δ8.62(s,3H),8.43(d,J=8.0Hz,1H),7.99(d,J=10.7Hz,1H),7.35(s,1H),5.59(s,2H),4 .70(d,J=6.0Hz,2H),2.55(s,3H),1.88(hept,J=7.1Hz,2H),0.88(t,J=7.3Hz,3H).MS(ESI)m / z[M+H]+:412.2.

[0187] Example 17 Preparation of Compound 17

[0188] To a mixture of anhydrous sodium sulfate (2.25 eq), 2-hydroxyacetic acid (1.45 eq), and compound 16 (100 mg) were added 2.4 mL of water and 3.0 mL of tetrahydrofuran. After stirring at room temperature for 15 minutes, N-methylmorpholine (1.10 eq) was added. After stirring at room temperature for 15 minutes, EDCI (2 eq) was added and stirred at room temperature for 3 hours. The reaction of compound 16 was monitored by HPLC for completion. The product was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and the solvent was removed by spin drying. The product was then purified by silica gel column chromatography (DCM:MeOH) to obtain 82 mg of compound 17, a yield of 72%.

[0189] 1 H NMR (400MHz, DMSO) δ8.41(d,J=8.9Hz,1H),7.77(d,J=11.0Hz,1H),7.30(s,1H),6.52(s,1H),5.58(d,J=5.4Hz,1H),5.49(t,J=5. 7Hz,1H),5.20(t,J=13.9Hz,2H),3.96(d,J=5.5Hz,2H),2.55(s,3H),1.96–1.78(m,2H),0.87(t,J=7.2Hz,3H).MS(ESI)m / z[M+H] + :470.2.

[0190] Example 18 Preparation of Compound 18

[0191] Referring to the preparation method of Example 17, using compound 3-1 and compound 16 as starting materials, 78 mg of compound 18 was prepared with a yield of 63%.

[0192] 1H NMR (400MHz, DMSO-d6) δ8.36(d,J=8.4Hz,1H),7.78(d,J=10.9Hz,1H),7.31(s,1 H),6.52(s,0H),5.58–5.48(m,1H),5.38(d,J=5.3Hz,1H),5.21(q,J=19.0Hz,2H ),3.62(d,J=5.2Hz,1H),2.39(s,4H),1.86(dt,J=14.3,7.1Hz,2H),1.14(q,J=7 .3Hz,2H),0.87(t,J=7.2Hz,3H),0.38(dd,J=20.9,5.6Hz,4H).MS(ESI)m / z[M+H] + :510.2.

[0193] Example 19 Preparation of Compound 19

[0194] Referring to the preparation method of Example 17, using compound 4-1 and compound 16 as starting materials, 74 mg of compound 19 was prepared with a yield of 60%.

[0195] 1 H NMR (400MHz, DMSO-d6) δ8.37(d,J=9.0Hz,1H),7.77(d,J=11.0Hz,1H),7.30( s,1H),6.51(s,1H),5.58(q,J=6.7Hz,1H),5.49(d,J=5.2Hz,1H),5.35–5.06( m,2H),3.60(t,J=5.7Hz,1H),2.39(s,3H),1.85(dq,J=14.2,7.1Hz,2H),1.24 (q,J=8.1Hz,1H),0.87(t,J=7.3Hz,3H),0.59-0.32(m,4H).MS(ESI)m / z[M+H] + :510.2.

[0196] Example 20 Preparation of Compound 20

[0197] Referring to the preparation method of Example 17, using compound 5-1 and compound 16 as starting materials, 70 mg of compound 20 was prepared with a yield of 58%.

[0198] 1H NMR(400MHz,DMSO-d6)δ8.42(d,J=8.7Hz,1H),7.78(d,J=11.0Hz,1H),7.30(s,1H) ,6.52(s,1H),5.55(dt,J=9.3,5.0Hz,1H),5.29–5.12(m,2H),4.66(d,J=4.7Hz,1H ),4.05(dt,J=12.1,6.0Hz,1H),2.39(s,3H),2.13(dd,J=10.7,5.4Hz,2H),1.86(h ept,J=7.1Hz,2H),1.09(d,J=6.2Hz,3H),0.87(t,J=7.3Hz,3H).MS(ESI)m / z[M+H] + :498.2.

[0199] Example 21 Preparation of Compound 21

[0200] Referring to the preparation method of Example 17, using compound 6-1 and compound 16 as starting materials, 75 mg of compound 21 was prepared with a yield of 62%.

[0201] 1 H NMR (400MHz, DMSO-d6) δ8.41(d,J=8.7Hz,1H),7.78(d,J=11.0Hz,1H),7.30(s,1 H), 6.53 (s, 1H), 5.57 (dt, J = 8.8, 4.5Hz, 1H), 5.22 (d, J = 2.7Hz, 2H), 4.64 (d, J = 4. 5Hz,1H),4.05(dt,J=11.9,6.1Hz,1H),2.39(s,3H),2.17–2.04(m,2H),1.86(he pt,J=7.1Hz,2H),1.08(d,J=6.1Hz,3H),0.87(t,J=7.3Hz,3H).MS(ESI)m / z[M+H] + :498.2.

[0202] Biological activity test

[0203] 1. In vitro anti-tumor activity detection of the disclosed loaded compounds

[0204] Purpose of the experiment: To detect the in vitro inhibitory activity of the compounds disclosed herein against NCI-N87 (human gastric cancer cells), Calu-3 (human lung adenocarcinoma cells), MDA-MB-453 (human breast cancer cells), KPL-4 (human breast cancer cells), or MDA-MB-468 (human breast cancer cells).

[0205] Take tumor cells NCI-N87 (source: ATCC, catalog number: CRL-5822), Calu-3 (source: ATCC, catalog number: HTB-55), MDA-MB-453 (source: ATCC, catalog number: HTB-131), KPL-4 (source: Nanjing Kebai Biological, catalog number: CBP60379) or MDA-MB-468 (source: ATCC, catalog number: HTB-132) in the logarithmic growth phase and add them to the cell plate at a number of 5000 cells / well. Place the cell plate in a 37°C, 5% CO2 cell culture incubator and incubate for 12-16 hours. Add 100 μl of sample to each well (starting at 10 μM, 4-fold dilution, 10 concentrations), shake gently and place in the incubator for incubation. After incubation for 48 hours, add 70 μL CellTiter-Glo TM (Promega, Cat. No. G7572) working solution was added, gently shaken to lyse the cells, and the plate was read on a microplate reader. The cell proliferation inhibition rate was calculated as follows: Cell proliferation inhibition rate = (1 - sample well / control well) × 100%. GraphPad Prism 8.0 software was used to plot the logarithm of sample concentration against cytotoxicity % on the ordinate. Nonlinear regression (curve fit) analysis was performed on the data to obtain the IC value for each sample. 50 The specific results are shown in Table 1-1 and Table 1-2.

[0206] Table 1-1 In vitro activity test results of the disclosed compounds

[0207] Table 1-2 In vitro activity test results of the disclosed compounds

[0208] The experimental results show that the disclosed compounds have significant proliferation inhibitory activity against NCI-N87, Calu-3, MDA-MB-453, KPL-4 or MDA-MB-468.

[0209] 2. Pharmacokinetics of the Disclosed Compounds in Mice

[0210] Experimental purpose: To evaluate the metabolic kinetics of the compounds disclosed in this disclosure in mice.

[0211] Balb / c mice were randomly divided into 12 groups (half male and half female) and injected once with the sample (Formulation A: 5% DMSO + 95% (15% sulfobutyl-β-cyclodextrin-normal saline); Formulation B: 5% DMSO-10% Solutol HS15-85% normal saline, diluted according to the dose). Plasma was collected at different points before administration and 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, and 24 hours after administration. The plasma sample concentrations were detected by LC-MS, and the pharmacokinetic parameters were calculated as shown in Table 2-1.

[0212] Table 2-1 PK parameters of the disclosed compounds in mice

[0213] The experimental results show that the compound of the present disclosure has a shorter in vivo half-life in mice. When it is used as a loading compound of ADC, the ADC can be cleared more quickly when the loading is shed in the body, and has better in vivo safety.

[0214] 3. Pharmacokinetics of the Disclosed Compounds in Rats

[0215] Experimental purpose: To evaluate the metabolic kinetics of the compounds of the present disclosure in rats.

[0216] SD rats (Beijing Weitonglihua Experimental Animal Technology Co., Ltd.) were randomly divided into groups of 6 rats per group, half male and half female, and injected once with the sample (preparation A is: 5% DMSO + 95% (15% sulfobutyl-β-cyclodextrin-normal saline), diluted according to the dose). Plasma was collected at cross points before administration and 5 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, and 24 hours after administration. The plasma sample concentrations were detected by LC-MS, and the pharmacokinetic parameters were calculated. The results are shown in Table 3-1.

[0217] Table 3-1 PK parameters of the disclosed compounds in rats

[0218] The experimental results show that the disclosed compounds also have a shorter in vivo half-life and a faster in vivo clearance rate in rats.

[0219] 4. In vitro plasma stability of the disclosed compounds

[0220] Take 398 μL of plasma, preheat to 37°C, and incubate for 15 minutes. Add 2 μL of sample solution to the plasma to a final concentration of 5 μM. Incubate the solution at 37°C. At 0, 15, 30, 60, and 120 minutes, take 50 μL of the solution and add it to 450 μL of ice-cold acetonitrile (containing the internal standard). Vortex the solution for 10 minutes, centrifuge, and determine the remaining amount of unchanged substrate by LC-MS / MS. See Table 4-1 for detailed results.

[0221] Table 4-1 Plasma stability of the disclosed compounds

[0222] The experimental results show that the disclosed compounds have good plasma stability.

[0223] 5. Repeated-dose toxicity study of the disclosed compounds in rats

[0224] Preparation of test sample: Weigh the test sample according to the predetermined weight into a glass bottle; first add 1 mL of DMSO and mix thoroughly. After the test sample is dissolved, add 1 mL of Solutol HS-15 and mix thoroughly. After that, add 8 mL of sodium chloride injection and vortex to mix thoroughly to obtain a clear and transparent solution.

[0225] SD rats (purchased from Beijing Weitonglihua) were used as test animals and were administered compound 2 and the positive control Dxd via tail vein injection for 7 consecutive days. Both compound 2 and the positive control Dxd were set at two doses of 0.3 mg / kg and 1.0 mg / kg. During the acclimation period, cage-side observations were conducted once a day; during the dosing period, all animals were clinically observed once in the morning and once in the afternoon. The responses of the skin, fur, eyes (sclera), ears, nose, mouth, chest, abdomen, urogenital area, limbs, as well as respiration, movement, urination, defecation (urine and feces color, etc.) and behavioral changes were recorded. Daily weighing data of the animals in the main test group were recorded. For animals planned for autopsy, the final body weight was measured before autopsy (fasting). The food intake of the test animals was also recorded. Specific test results are shown in Table 5-1.

[0226] Table 5-1 Results of repeated-dose toxicity experiments of the disclosed compounds in rats

[0227] Among them, ♂ represents male and ♀ represents female;

[0228] After the administration, gross autopsy was performed on D8 after the administration, and focal / punctate dark red discoloration was found in the lungs of some rats that died in the Dxd control group, while this symptom was not found in the compound 2 dose group.

[0229] The above experimental data show that the compound 2 of the present disclosure has lower in vivo toxicity and better in vivo safety than the positive control Dxd.

[0230] In the present disclosure, the comparative compound Dxd refers to the following compound, which can be prepared according to the published document WO2014057687A.

Claims

1. A compound of formula II or a pharmaceutically acceptable salt or a stereoisomer thereof: in, R1 is selected from H, halogen, OH, SH, NH2, C 1-4 Alkyl, C 1-4 Haloalkyl or C 1-4 Alkoxy; R2 is selected from H, halogen, C 1-4 Alkyl or C 1-4 Alkoxy; Or R1 and R2 are cyclized to -O-(CH2) m -O-, wherein m is selected from 1, 2 or 3; R3 and R4 are each independently selected from H, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Haloalkyl or C 1-4 Haloalkoxy; Or R3 and R4 cyclize to -(CH2) k -, wherein k is selected from 1, 2, 3 or 4; X is selected from H, OH, HO-CH(R5)-(CH2) p -CO-NH- or -N(R6)(R7), wherein p is selected from 0, 1 or 2; R5 is selected from H, C 1-4 Alkyl, C 1-4 Haloalkyl, 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl; R6 is selected from H, C 1-4 Alkyl or C 1-4 Haloalkyl; R7 is selected from H or R8-S(O)2-; R8 is selected from C 1-4 Alkyl; and t is selected from 0, 1, 2, 3, 4 or 5; And the compound of formula II does not include any of the following compounds:

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R1 is C 1-4 alkyl, and R2 is halogen; or, R1 is methyl, and R2 is F; or R1 is H, and R2 is H; or R1 and R2 are cyclized to -O-CH2-O-; or, R1 is NH2, and R2 is H or halogen; or, R1 is NH2, and R2 is H or F.

3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R3 is H and R4 is H; or R3 is H and R4 is C 1-4 Alkyl; or R3 is H, and R4 is methyl; or R3 and R4 are cyclized to form -CH2-CH2-.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein X is HO-CH(R5)-(CH2) p -CO-NH-, and p is selected from 0, 1, 2; or X is selected from OH or NH2; or X is H, and t is 0; or X is -N(R6)(R7).

5. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein the compound of formula II is a compound of formula IIa, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: in, R1, R2, R3 and R4 are as defined in any one of claims 1 to 3, and X1 is selected from H, HO-CH(R5)-(CH2) p -CO-, p is selected from 0, 1, 2; R5 is selected from H, C 1-4 Alkyl, 3-6 membered cycloalkyl or 3-6 membered heterocycloalkyl.

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R1 is selected from methyl or methoxy; or R1 is methyl.

7. The compound according to claim 5 or 6, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R2 is selected from F or Cl; or R2 is F.

8. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R1 is methyl, and R2 is F.

9. The compound according to any one of claims 5 to 8, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R3 and R4 are cyclized to -(CH2) k -, and k is 2; or R3 is H, and R4 is H.

10. The compound according to any one of claims 5 to 9, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein X1 is HO-CH(R5)-(CH2) p -CO-, p is selected from 0 or 1, and R5 is selected from H, C 1-4 Alkyl or 3-6 membered cycloalkyl; or, X1 is HO-CH(R5)-(CH2) p -CO-, p is selected from 0 or 1, and R5 is selected from H, methyl or cyclopropyl; or, X1 is HO-CH(R5)-CO-, and R5 is selected from H or 3-6 membered cycloalkyl; or, X1 is HO-CH(R5)-CO-, and R5 is selected from H or cyclopropyl; or, X1 is HO-CH(R5)-CH2-CO-, and R5 is C 1-4 alkyl; or, X1 is HO-CH(R5)-CH2-CO-, and R5 is methyl; or X1 is selected from the following groups: H, 11. The compound according to any one of claims 5 to 10, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein the compound of formula IIa is selected from the compound of formula IIa-1, the compound of formula IIa-2, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof; in, R1, R2 and X1 are as defined in any one of claims 5 to 8 and 10.

12. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein the compound of formula II is a compound of formula IIb, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: in, R1, R2, R3 and R4 are as defined in any one of claims 1 to 3; X2 is selected from H, OH or -N(R6)(R7); R6 is selected from H or C 1-4 Alkyl; R7 is selected from H or R8-S(O)2-; R8 is C 1-4 Alkyl; and q is selected from 0, 1, 2, 3, 4.

13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R1 is selected from methyl, and R2 is selected from H, Cl, F; or R1 and R2 are cyclized to -O-(CH2) m -O-, and m is selected from 1 or 2.

14. The compound according to claim 12 or 13, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein R3 and R4 are both H; or R3 is H, and R4 is methyl.

15. A compound according to any one of claims 12 to 14, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein X2 is selected from H and q is 0; or, X2 is selected from OH or -N(R6)(R7) and q is 0, 1, 2, 3 or 4; or, X2 is selected from OH or -N(R6)(R7), q is 0, 1, 2, 3 or 4, R3 and R4 are both H, R1 is selected from methyl and R2 is selected from H, Cl or F, or R1 and R2 are cyclized to -O-(CH2) m -O-, wherein m is selected from 1 or 2; or, X2 is selected from H, OH, NH2 or N(i-Pr)-S(O)2-CH3.

16. The compound according to any one of claims 12 to 15, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein the formula IIb is a compound of formula IIb-1, a compound of formula IIb-2, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof; in, R1, R2, X2 and q are as defined in any one of claims 12-13 and 15.

17. The compound according to claim 5 or 12, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, wherein the compound of formula IIa is selected from the following compounds, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof: The formula IIb is selected from the following compounds or pharmaceutically acceptable salts or stereoisomers thereof:

18. A pharmaceutical composition comprising the compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof and a pharmaceutically acceptable excipient.

19. Use of the compound according to any one of claims 1 to 17 or its pharmaceutically acceptable salt or stereoisomer thereof or the pharmaceutical composition according to claim 18 in the preparation of a medicament for treating tumors.

20. A method for treating a tumor, comprising administering the compound according to any one of claims 1 to 17 or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, or the pharmaceutical composition according to claim 18 to an individual in need thereof.

Citation Information

Patent Citations

  • Antibody-drug conjugate

    WO2014057687A1

  • Antibody-drug conjugate

    CN104755494A

  • Novel camptothecin derivative, and preparation method and application thereof

    CN110845559A

  • Deuterated camptothecin derivative and antibody drug conjugate thereof

    CN113943310A

  • Dideuterated camptothecin derivative and preparation method thereof

    CN117105948A

Cited By

  • Deuterated camptothecin derivative as well as preparation method and application thereof

    CN119912467A

  • Pharmaceutical composition for treatment and / or prevention of cancer

    CN123036312A

  • Pharmaceutical composition for treating and / or preventing cancer

    WO2025206085A1

  • Anti-CDH6 antibody, conjugate thereof and use thereof

    WO2026130458A1

  • Long-circulating pharmaceutical preparation, and preparation method therefor and pharmaceutical use thereof

    WO2026149470A1